V. Bellein

Metabolic syndrome: a major risk factor for atherosclerosis in HIV-infected patients (SHIVA study).

N. Roudaut, L. Bressollette, O. Vandhuick, 2008, Presse medicale.

Long‐term assessment of nevirapine‐containing highly active antiretroviral therapy in antiretroviral‐naive HIV‐infected patients: 3‐year follow‐up of the VIRGO study

F. Raffi, P. Perre, V. Reliquet, 2006, HIV medicine.

The Virgo Study: Nevirapine, Didanosine and Stavudine Combination Therapy in Antiretroviral-Naive HIV-1-Infected Adults

W. Rozenbaum, F. Raffi, V. Ferré, 1999, Antiviral therapy.

HIV-1 genetic diversity in Western Brittany, France.

F. Brun-Vézinet, B. Picard, S. Vallet, 2002, FEMS immunology and medical microbiology.

Impact of atazanavir-based HAART regimen on the carotid intima–media thickness of HIV-infected persons: a comparative prospective cohort

S. Ansart, L. Bressollette, S. Vallet, 2010, AIDS.

Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study).

N. Roudaut, L. Bressollette, O. Vandhuick, 2006, Atherosclerosis.

Correlations between carotid IMT, factor VIII activity level and metabolic disturbances: a cardio-vascular risk factor in the HIV positive persons.

L. Bressollette, O. Vandhuick, S. Vallet, 2007, Current HIV research.